Dr Reddy's cuts price of cardiovascular drug Cidmus
Dr. Reddy’s Laboratories Ltd announced a significant price reduction of its trusted cardiovascular drug Cidmus.
Dr. Reddy’s Laboratories Ltd
Hyderabad: Dr. Reddy's Laboratories Ltd announced a significant price reduction of its trusted cardiovascular drug Cidmus. It is a pharmaceutical composition containing a combination of sacubitril and valsartan, indicated for heart failure patients with reduced ejection fraction.
Cidmus tablets are available in three strengths – 50mg, 100mg and 200mg, to be taken twice a day. Following the price reduction, it will be priced at Rs 29 for 50mg (down from Rs 78.32), Rs 49 for 100mg (down from Rs 83.86) and Rs 79 for 200mg (down from Rs 96.71) per tablet.
The product will be manufactured in-house. The Active Pharmaceutical Ingredient (API) of Cidmus is manufactured at a USFDA-approved facility. Cidmus has a co-crystal formulation that enhances bioavailability, solubility and physical and chemical properties of the drug.
There is a growing incidence of chronic diseases in India, and heart failure is one of them. It is estimated that India has between 8-10 million heart failure patients. Dr Reddy's acquired the cardiovascular brand Cidmus from Novartis AG in 2022 for the India market.
Driven by the company's strong marketing and distribution network, Cidmus has reached over 1 lakh patients in India with a market share of 32 per cent.
